Welcome Guest
Home > Clinical Breast Cancer > Volume 7 |  Issue 7 > Article Abstract

Abstract
Back to TOC
References
X

Note:- Read as Author : Article Title : Source : Year : Publisher

    1.  Aloe A, Bove L, Pace A, et al. Paclitaxel neurotoxicity: clinical and neurophysiological study in 23 patients. It J Neurol Sci 1996; 18:73-79.
    2.  Chaudry V, Rowinsky EK, Sartorius P, et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994; 35:304-311.
    3.  De Vries EG, Guchelaar HJ, ten Napel CH, et al. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review. Clin Oncol (R Coll Radiol) 1994; 6:40-48.
    4.  Mielke S, Mross K, Sparreboomb A, et al. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006; 42:24-30.
    5.  Berry DA, Winer EP, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol 2004; 22:2061-2068.
    6.  Bogliun G, Cavaletti G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology 2003; 61:1297-1300.
    7.  Aaronson NK, Heimans JJ, Postma TJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005; 41:1135-1139.
    8.  Antonini-Cappellini G, Marchetti P, Urien S, et al. Weekly administration of paclitaxel: theoretical and clinical basis. Crit Rev Oncol Hematol 2002; 44:S3-S13.
    9.  Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005; 10:370-381.
    10.  Gerds TA, Mielke S, Mross K, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusion over 1 versus 3 h. Anticancer Drugs 2003; 14:785-792.
    11.  Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11:4843-4850.
    12.  Eniu A, Palmieri FM, Perez EA, et al. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005; 10:665-685.
    13.  Bove L, Nisticò C, Pace A, et al. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996; 61:409-411.
    14.  Keller SD, Kosinski M, Ware JE, et al. SF-36 Physical and Mental Summary Scales: A User's Manual 3rd ed Boston, MA:The Health Institute, New England Medical Centre; 1994.
    15.  Seidman A. “Will weekly work”? Seems to be so... J Clin Oncol 2005; 23:5873-5874.
    16.  Honore S, Pasquir E, Pourroy B, et al. Anti-angiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65:2433-2440.
    17.  Abi-Raad R, Assaad SI, Taghian AG, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol 2005; 23:1951-1961.
    18.  Buzdar AU, Green MC, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3-weeks paclitaxel. J Clin Oncol 2005; 23:5983-5992.
    19.  Berry D, Cirrincione L, Seidman AD, et al. CALGB 9840: phase III study of weekly paclitaxel via 1hour infusion versus standard 3hour infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22((14 suppl)):14S-14S.
    20.  Cognetti F, Frontini L, Nistic• C, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology 2005; 68:356-363.
    21.  Igishi T, Kawasaki Y, Yasuda K, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003; 65:224-228.
    22.  Igishi T, Kawasaki Y, Yasuda K, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66:347-352.
    23.  Albanel J, Albanell J, Hudis CA, Seidman AD, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-3361.
    24.  Irwin DH, Perez EA, Vogel CL, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19:4261-4223.
    25.  Ostenstad B, Sommer HH, Wist EA, et al. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 2004; 43:11-14.
    26.  Akerley W, Egorin MJ, Herndon JE, et al. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 2003; 97:2480-2486.
E-mail this article
X

Fields marked with an asterisk * are mandatory.

* Your Name:
* Your Email:
* Friend's Name:
* Friend's Email:
Message:
 
Send CC to self
 
 
Add to Favorites
X
  • Volume 7
  •  Issue 7
    • Publication Date: April 2007


Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?


Andrea Pace, Cecilia Nisticò, Federica Cuppone, Emilio Bria, Edvina Galié, Giuliana Graziano, Guido Natoli, Isabella Sperduti, Bruno Jandolo, Francesca Calabretta, Silverio Tomao, Edmondo Terzoli

Purpose: The rationale for intensification strategies is that more frequent exposure to chemotherapeutics could enhance antitumor activity. Several trials investigated weekly paclitaxel administration, but there are no clear data concerning peripheral neurotoxicity. The aim of this study was to assess the incidence of peripheral neurotoxicity in patients affected by advanced breast cancer treated with weekly paclitaxel. Patients and Methods: Neurotoxicity was assessed with neurologic and neurophysiologic evaluation before treatment and after 12 weeks and 24 weeks. A total neurotoxicity score was assigned to each patient on the basis of neurophysiologic and neuropathic signs and symptom changes. Seventeen patients entered the study. Results: After 12 weeks of treatment, 71% showed moderate clinical and/or neurophysiologic signs of neurotoxicity; after 24 weeks, the incidence of neurotoxicity increased to 96%. Sural amplitude at the 24 weeks examination significantly decreased from basal mean value (13.5 μv, standard deviation [SD] 6 μv vs. 7 μv, SD 5.9 μv, respectively; P = 0.01), whereas median sensory amplitude decreased after 24 weeks from 10.3 μv, SD 6.2 μv to 4.9 μv, SD 3.8 μv (P = 0.001). In a subset of 11 patients, we obtained a follow-up examination after 6 months from the end of treatment. In all patients, examined signs and symptoms of neurotoxicity improved with recovery of subjective neuropathic symptoms and neurophysiologic findings. Conclusion: Our results demonstrate, in a little population of patients evaluated with a comprehensive neurologic assessment, that weekly paclitaxel is related to a very high incidence of peripheral neurotoxicity. Follow-up data obtained in a subset of patients indicate that peripheral neurotoxicity is reversible.

Key words: Amplitude, Chemotherapy, Neurophysiology


  1. https://www.ceteresopolitano.org/
  2. https://www.crossingstoronto.com/
  3. https://www.jediism.org/
  4. https://www.badenumc.org/
  5. https://www.johnsevierchapter.org/
  6. https://www.trinitychapelmn.org/
  7. https://www.photogearnews.com/
  8. https://www.alz-nova.org/
  9. https://www.cigjournals.com/
  10. https://summa-edu.com/
  11. https://cpawilmingtonnc.org/
  12. https://bimometals.com/
  13. https://sosenvironmental.com/
  14. https://thefriary.org/
  15. https://post5theatre.org/
  1. KELUARAN SGP
  2. TOGEL